Changyi Lin, Fu-Ju Chou, Jieyang Lu, Wanying Lin, Matthew Truong, Hao Tian, Yin Sun, Jie Luo, Rachel Yang, Yuanjie Niu, Rosa Nadal, Emmanuel S Antonarakis, Carlos Cordon-Cardo, Deepak Sahasrabudhe, Chi-Ping Huang, Shuyuan Yeh, Gonghui Li, Chawnshang Chang
Anti-androgen therapy with Enzalutamide (Enz) has been used as a therapy for castration resistant prostate cancer (CRPC) patients after development of resistance to chemotherapy with Docetaxel (Doc). The potential impacts of Doc-chemotherapy on the subsequent Enz treatment, however, remain unclear. Here we found the overall survival rate of patients that received Enz was significantly less in patients that received prior Doc-chemotherapy than those who had not. In vitro studies from 3 established Doc resistant CRPC (DocRPC) cell lines are consistent with the clinical findings showing DocRPC patients had decreased Enz-sensitivity as well as accelerated development of Enz-resistance via enhanced androgen receptor (AR) splicing variant 7 (ARv7) expression...
September 10, 2020: Aging